MICHAEL YOUNG: Open Payments
NPI 1316458862 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,761 in 122 payments from 16 companies in 2025. Trend: 2023 $1,986 · 2024 $1,993 · 2025 $1,761
Food & beverage: $1,761
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 42 | $504 |
| ABBVIE INC. | 19 | $247 |
| UCB, Inc. | 15 | $217 |
| Janssen Biotech, Inc. | 10 | $137 |
| GlaxoSmithKline, LLC. | 6 | $99 |
| Organon LLC | 6 | $96 |
| Novartis Pharmaceuticals Corporation | 5 | $95 |
| AstraZeneca Pharmaceuticals LP | 4 | $71 |
| Fresenius Kabi USA, LLC | 3 | $62 |
| Lilly USA, LLC | 3 | $57 |
Products named: ENBREL, TAVNEOS, Bimzelx, RINVOQ, TREMFYA, BENLYSTA, HADLIMA, SAPHNELO.
Industry payments across UT — which companies pay providers there.
